We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nuvo Pharmaceuticals Inc | TSX:MRV | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.35 | 1.34 | 1.35 | 0 | 00:00:00 |
Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced it expects to release its third quarter 2021 financial results before markets open on Monday, November 15, 2021.
The Company will subsequently hold a conference call the same day, Monday, November 1, 2021 at 11:00 a.m. ET, hosted by Jesse Ledger, Miravo’s President & Chief Executive Officer and other senior management. A question-and-answer session will follow the corporate update.
CONFERENCE CALL DETAILS
DATE: Monday, November 15, 2021
TIME: 11:00 a.m. ET
DIAL-IN NUMBERS: (289) 536-4777 or 1 (888) 550-2239
The audio webcast and webcast replay can be accessed at:
https://onlinexperiences.com/Launch/QReg/ShowUUID=1E07F0A9-7B64-4D3F-9EAA-D9A1C0CE92B9
About Miravo Healthcare
Miravo is a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S, Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit www.miravohealthcare.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005317/en/
Investor Relations Stefan Eftychiou 905 326 1888 ext 60 stefan@bristolir.com
1 Year Nuvo Pharmaceuticals Chart |
1 Month Nuvo Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions